Omeros Corp
NASDAQ:OMER
Omeros Corp
Research & Development
Omeros Corp
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Omeros Corp
NASDAQ:OMER
|
Research & Development
-$85.2m
|
CAGR 3-Years
25%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-7%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$14.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Omeros Corp
Glance View
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 213 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases and cancers. The Company’s lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and coronavirus (COVID-19). OMS906, the Company’s inhibitor of MASP-3, the alternative pathway of complement, is in a Phase 1 clinical trial.
See Also
What is Omeros Corp's Research & Development?
Research & Development
-85.2m
USD
Based on the financial report for Sep 30, 2025, Omeros Corp's Research & Development amounts to -85.2m USD.
What is Omeros Corp's Research & Development growth rate?
Research & Development CAGR 10Y
-7%
Over the last year, the Research & Development growth was 32%. The average annual Research & Development growth rates for Omeros Corp have been 25% over the past three years , 7% over the past five years , and -7% over the past ten years .
